Who We Are
Grounded in more than 20 years of ADC expertise, Byondis is evolving the field with novel payload platforms, advanced masking technology, and optimized linker and conjugation strategies. Our approach enables the development of ADCs with superior efficacy, duration of response, and safety to improve clinical outcomes and bring hope to patients facing difficult-to-treat cancers.
Leadership Team
Our management team has broad scientific, clinical, operational, and partnering experience.
Sustainability
We care – for each other, for partners, for patients and for society at large.
Partnering
To realize the full potential of our science, pipeline, and technology, we are open to collaborate and partner among research institutions and biopharmaceutical companies.
Pipeline
Our diverse pipeline of proprietary next-generation ADCs reflects our expertise in research, lead identification, preclinical/clinical development, process development and manufacturing.
Our Science
We employ the latest insights in tumor biology and immunology in our search for new molecular targets and development of new mechanisms for antibody-drug conjugates (ADCs) and small molecule programs.
